How Soon Wegovy Starts Working: A Week-by-Week Timeline

Step 1: Weeks 1–4, the first pen, and what your body is adjusting to

The first Wegovy pen contains a 0.25mg dose. Its job is to let your body adapt to semaglutide, not to drive rapid weight loss. Most people notice some reduction in appetite within this first month (food feels less urgent, portions feel more comfortable) but the scales may not shift much yet, and that is expected. The semaglutide overview explains how the medicine works at a receptor level: it slows gastric emptying and signals fullness to the brain, effects that take time to reach their full strength.

Gastrointestinal symptoms (nausea, mild discomfort, loose stools) are most common in this phase, particularly in the day or two after each injection. They usually settle within a week. Injecting after a light meal and staying well hydrated helps many people through this period, though the Patient Information Leaflet and your prescriber are the right sources for personal guidance. One practical detail worth knowing: keeping the pen in the fridge door at a consistent temperature (rather than in the main compartment where it may get too cold) means it is ready to use without any temperature-shock wait.

By the end of week four, your prescriber will typically move the dose to 0.5mg. The Wegovy treatment page covers what to expect at each stage in more detail.

Step 2: Weeks 5–16, stepping up through the dose ladder

The licensed titration continues in roughly four-week intervals: 0.25mg, then 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg. Some people move more slowly if they experience side effects; a prescriber decides the pace, not an automated system. This step-up phase is when many people report the clearest change in eating behaviour, hunger between meals reduces noticeably, and the impulse to eat past fullness weakens. Weight loss in this phase is real but variable. Some people lose a meaningful amount; others progress more slowly while their dose is still sub-therapeutic.

It is worth understanding why the schedule is structured this way. Each increment gives the body time to calibrate before the next increase. Skipping steps or rushing the titration raises the risk of side effects without improving long-term outcomes. If you are curious about the clinical reasoning behind this graduated approach, our page on how soon Wegovy starts working covers what the prescriber looks for at each review, including why patience at each dose level matters.

Nausea typically becomes less prominent as the weeks pass. The most common side effects across the STEP programme were gastrointestinal (nausea, vomiting, diarrhoea, constipation) and were generally mild to moderate, according to the STEP 1 trial published in the New England Journal of Medicine.

Step 3: Months 4–6, maintenance dose and measurable progress

Once you reach 2.4mg (or, for those progressing to the higher licensed dose, 7.2mg approved by the MHRA in April 2026), you are on the maintenance level. This is where the most consistent weight loss tends to occur. In the STEP 1 trial, participants on 2.4mg lost an average of around 15% of body weight over 68 weeks. That figure is an average across a large study population, some people lost considerably more, some less.

Six months is roughly when you can make a fair assessment of how the medicine is working for you at full dose, and our guide to when Wegovy starts working explains what to look for at each milestone along the way. NICE guidance for semaglutide notes that if weight loss is less than 5% after six months at the maintenance dose, continuing treatment should be reviewed. That review is a clinical conversation, not an automatic stop.

The cost of staying on treatment over these months is a practical reality. A factual overview of what Wegovy costs privately in the UK sets out how pricing is structured, including what a legitimate prescription service includes. For anyone thinking about what treatment could involve, the weight-loss treatment overview covers all the options currently available.

Realistic expectations: what shapes how quickly you respond

Wegovy works alongside, not instead of, dietary changes and increased activity. People who make consistent lifestyle adjustments alongside the injections tend to see better outcomes in trial data, that pattern holds across the semaglutide studies. Biology also plays a role: body composition, metabolic rate, and which conditions are being treated alongside weight all influence the pace of progress.

The NHS guidance on semaglutide on the NHS website explains that this is a medicine for long-term weight management, not a short course. Stopping it without a plan typically leads to some weight regain over time, that is a biological reality, not a failure. A prescriber can discuss maintenance strategies as part of ongoing clinical review.

If at any point you experience severe, persistent abdominal pain that radiates to the back, seek urgent medical attention. This could indicate pancreatitis, a rare but serious side effect highlighted by MHRA safety communications. Other symptoms to report to a clinician promptly include signs of a severe allergic reaction or significant mood changes.

Starting Wegovy through a regulated service means a real clinician reads your consultation (not software) before any prescription is issued. If you want to explore whether Wegovy could be right for you, start your free consultation and our GPhC-registered prescribers will review your details the same day.